CN115160559A - 一种peg化雷帕霉素化合物及其制备方法与应用 - Google Patents
一种peg化雷帕霉素化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN115160559A CN115160559A CN202110365285.9A CN202110365285A CN115160559A CN 115160559 A CN115160559 A CN 115160559A CN 202110365285 A CN202110365285 A CN 202110365285A CN 115160559 A CN115160559 A CN 115160559A
- Authority
- CN
- China
- Prior art keywords
- rapamycin
- pegylated
- peg
- compound
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 156
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 155
- -1 rapamycin compound Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 134
- 239000003814 drug Substances 0.000 claims abstract description 52
- 229940079593 drug Drugs 0.000 claims abstract description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 21
- 229940005267 urate oxidase Drugs 0.000 claims abstract description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108010092464 Urate Oxidase Proteins 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims abstract description 8
- 230000028993 immune response Effects 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 230000001603 reducing effect Effects 0.000 claims abstract description 6
- 239000003054 catalyst Substances 0.000 claims abstract description 3
- 101000634900 Homo sapiens Transcriptional-regulating factor 1 Proteins 0.000 claims abstract 3
- 241001506137 Rapa Species 0.000 claims abstract 3
- 102100029446 Transcriptional-regulating factor 1 Human genes 0.000 claims abstract 3
- 239000002105 nanoparticle Substances 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 239000012074 organic phase Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000011068 loading method Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000012931 lyophilized formulation Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims 1
- 229940125385 biologic drug Drugs 0.000 claims 1
- 239000008380 degradant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 8
- 238000003756 stirring Methods 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000002245 particle Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 238000007710 freezing Methods 0.000 description 12
- 230000008014 freezing Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000004945 emulsification Methods 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 9
- 230000010494 opalescence Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000003223 protective agent Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000000935 solvent evaporation Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000006058 immune tolerance Effects 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000013441 quality evaluation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyethers (AREA)
Abstract
本发明属于属于生物医药技术领域,涉及一种PEG化雷帕霉素化合物及其制备方法与应用。该化合物如式(I)所示,其中,n为10‑150。制备方法为将mPEG‑COOH溶于有机溶剂中,加入催化剂EDC·HCl和DMAP,以及RAPA,在10~40℃避光下搅拌反应。以及该化合物及其药物制剂在制备用于减少免疫应答的药物中的用途,可有效抑制生物药物如尿酸氧化酶等的抗药抗体生成,具有良好的临床应用前景,特别适合将其制备成纳米药物。
Description
技术领域
本发明属于生物医药技术领域,涉及一种PEG化雷帕霉素化合物及其制备方法与应用。
背景技术
2018年全球最畅销与销售额增长最大的TOP10药品中有8种为单克隆抗体。全球生物医药产业快速增长,但与小分子化药相比,大多数生物药物都具有免疫原性,进入机体后会引起免疫应答,产生抗药抗体,从而中和或改变生物药物的药物动力学和生物分布,更严重地可能诱导机体出现超敏反应等危及生命的毒副作用。因此,抑制生物药物治疗时抗药抗体的生成对提高生物药物的安全性和有效性非常关键。
免疫抑制剂是指对机体的免疫反应具有抑制作用的药物,能抑制与免疫反应有关细胞(T细胞和B细胞等巨噬细胞)的增殖和功能,从而能降低抗体免疫反应。免疫抑制剂主要用于器官移植抗排斥反应和自身免疫病如类风湿性关节炎、红斑狼疮、皮肤真菌病、膜肾球肾炎、炎性肠病和自身免疫性溶血贫血等。
雷帕霉素(rapamycin,RAPA),又称西罗莫司,是吸水链霉菌所产生的一种亲脂性三烯含氮大环内酯抗生素类免疫抑制剂,可用于治疗癌症、抗移植物排斥反应及其它免疫性疾病的辅助治疗。雷帕霉素可通过阻断哺乳动物雷帕霉素靶蛋白(mammalian target ofrapamycin,mTOR)参与的信号转导,阻止T细胞分化和树突状细胞成熟,从而发挥免疫抑制的作用。
Takashi K.Kishimoto首次报道负载免疫抑制剂-雷帕霉素的聚乳酸-羟基乙酸(poly(1actic acid-co-glycolic acid),PLGA)纳米粒具有免疫耐受性,可有效抑制生物药物的抗药抗体的生成(Nature nanotechnology,2016,11(10): 890-899),并将其定义为免疫耐受性纳米粒。上述文献报道将雷帕霉素包埋到PLGA载体上制备的雷帕霉素PLGA纳米粒具有诱导免疫耐受、抑制生物药物的抗药抗体生成的功能。PLGA为人工合成的高分子量化合物,其本身不具有药理作用,为一种药用辅料产品。
发明内容
本发明的第一目的是提供了一种PEG化雷帕霉素化合物,该化合物具有适宜的疏水雷帕霉素端和亲水PEG链端,是制备纳米粒的良好载体。
本发明的第二目的是提供了一种制备上述化合物的方法,反应条件温和、操作简单。
本发明的第三目的是提供了一种上述化合物的应用,将其制备成纳米药物、冻干制剂、药物组合物以及在制备用于减少免疫应答的药物中的用途。
一种如式(I)所示的PEG化雷帕霉素化合物,其中,n为10-150。
本发明还公开了一种上述的PEG化雷帕霉素化合物的制备方法,将 mPEG-COOH溶于有机溶剂中,加入催化剂EDC·HCl和MAP,以及RAPA,在10~40℃避光下搅拌反应。
在本发明的一实施例中,该制备方法的反应温度优选为20~30℃。
在本发明的一实施例中,所述的有机溶剂为二氯甲烷或氯仿中的一种或两种,优选为二氯甲烷。
在本发明的一实施例中,所述的mPEG-COOH与RAPA的摩尔比为 5∶1~1∶5,优选为3∶1-1∶3。
在本发明的一实施例中,还包括反应后的分离纯化步骤,所述的分离纯化步骤为透析纯化法或硅胶柱层析法。
在本发明的一实施例中,所述的透析纯化法使用透析袋和透析溶剂进行分离纯化。其中,所述的透析袋的截留分子量为500-5000,优选为1500。所述的透析溶剂为DMSO、卤代烃、四氢呋喃、超纯水中的一种或多种,优选为DMSO、超纯水中的一种或两种,更优选为DMSO和超纯水。
在本发明的一实施例中,所述的硅胶柱层析法洗脱方式为等度洗脱或梯度洗脱,优选为梯度洗脱。
在本发明的一实施例中,所述的梯度洗脱所使用的洗脱剂为二氯甲烷、乙酸乙酯、无水甲醇中的两种或多种,优选为二氯甲烷和无水甲醇的混合溶剂。其中,二氯甲烷与无水甲醇(v/v)的比为100∶1-10∶1,优选为50∶1-20∶1。
本发明还公开了一种纳米药物,其包括有效载药量的上述的PEG化雷帕霉素化合物,优选为,由有效载药量的上述的PEG化雷帕霉素化合物与游离雷帕霉素组成。
在本发明的一实施例中,所述的PEG化雷帕霉素纳米粒的粒径为5-1000 nm,优选为50-200nm。
在本发明的一实施例中,所述的PEG化雷帕霉素纳米粒的载药量为 15%-100%,优选为25%-85%。
本发明还公开了一种上述的纳米药物的制备方法,采用自下而上的方法制得,所述的PEG化雷帕霉素纳米粒的制备方法包括乳化/溶剂挥发法、纳米沉淀法、薄膜分散法、自组装法或SPG膜法乳化,优选为乳化/溶剂挥发法。
在本发明的一实施例中,所述的乳化/溶剂挥发法为将PEG化雷帕霉素化合物,或PEG化雷帕霉素化合物和雷帕霉素溶解在有机溶剂中形成有机相,然后加入到含有聚乙烯醇的水相中,通过高速搅拌、超声、漩涡振荡和/或用高压匀质机制成水包油乳状液,最后经蒸发、挥干有机溶剂得到PEG化雷帕霉素纳米粒溶液。
在本发明的一实施例中,该乳化/溶剂挥发法所用的有机溶剂为氯仿、 CH2Cl2中的一种或两种,优选为CH2Cl2。
在本发明的一实施例中,该乳化/溶剂挥发法的所述的PEG化雷帕霉素在所述的有机相中的浓度为0.1-10mg/mL,优选为0.5-5mg/mL。
在本发明的一实施例中,该乳化/溶剂挥发法还包括游离雷帕霉素,所述的游离雷帕霉素/所述的PEG化雷帕霉素的比例为0-20/1(w/w),优选为 1/5-5/1(w/w)。
在本发明的一实施例中,该乳化/溶剂挥发法的所述的有机相/所述的水相的比例为1/1-1/100(v/v),优选为1/2-1/10(v/v)。
在本发明的一实施例中,该乳化/溶剂挥发法的所述的聚乙烯醇在所述的水相中的浓度为0-5%(w/v),优选为0.5%-2%(w/v)。
本发明还公开一种冻干制剂,其由上述的PEG化雷帕霉素纳米粒的水溶液和冻干保护剂冻干制得。
在本发明的一实施例中,所述的冻干保护剂为蔗糖、乳糖、甘露醇、葡萄糖、海藻糖、麦芽糖中的一种或多种。
在本发明的一实施例中,所述的冻干保护剂在所述的PEG化雷帕霉素纳米粒的水溶液中的浓度为0.1%-20%(w/v),优选为2%-8%(w/v)。
在本发明的一实施例中,在制备冻干制剂所用的预冻温度为<-10℃,优选为-30℃--50℃。预冻方式为快冻和慢冻,优选为快冻。
本发明还公开了一种药物组合物,其包括治疗有效剂量的上述的PEG化雷帕霉素化合物及可药用的载体。
在本发明的一实施例中,还包括生物药物。
在本发明的一实施例中,所述的生物药物为尿酸氧化酶、酶和辅酶类药物、核酸及其降解物和衍生物类药物、细胞生长因子或细胞因子中的一种或多种,优选为尿酸氧化酶。
本发明还公开了上述的PEG化雷帕霉素化合物,上述的纳米药物,上述的冻干制剂或上述的药物组合物在制备用于减少免疫应答的药物中的用途。
与现有技术相比,本发明的有益效果如下:
1.本发明的PEG化雷帕霉素结构组成明确,纯度高,具有适宜的疏水雷帕霉素端和亲水PEG链端,是制备纳米粒良好载体。
2.本发明的PEG化雷帕霉素纳米粒由PEG化雷帕霉素和雷帕霉素组成,以PEG化雷帕霉素为载体,PEG化雷帕霉素分子中雷帕霉素部分与游离雷帕霉素分子构成纳米粒疏水的核,纳米粒表面有亲水PEG链段,在水中分散稳定性高。
3.本发明的PEG化雷帕霉素纳米粒具有免疫靶向性,可在免疫器官如脾脏富集并缓释药物,有效抑制生物药的抗药抗体生成,产生免疫耐受性;本发明PEG化雷帕霉素纳米粒中雷帕霉素的含量高,具有比雷帕霉素PLGA纳米粒更好地抑制抗药抗体生成的功效,同时也避免长期多剂量给药雷帕霉素带来的毒副作用,不含有PLGA等药用辅料。
本发明将亲水性聚乙二醇通过酯化反应连接到疏水性雷帕霉素上制得两亲性PEG化雷帕霉素,然后将PEG化雷帕霉素单独或PEG化雷帕霉素与雷帕霉素一起制成具有良好水溶性的PEG化雷帕霉素纳米粒,能够有效用于抑制生物药如尿酸氧化酶等的抗药抗体生成,具有良好的临床应用前景。
附图说明
图1为mPEG-COOH的的1H NMR和13C NMR谱图(CDCl3为溶剂),其中,图1(a)为1H NMR图谱的全图,图1(b)为1H NMR图谱的谱图上各峰的归属,图1(c)为13C NMR谱图的全图,图1(d)为13C NMR谱图的局部放大图,图1(e)为13C NMR图谱的谱图(CDCl3为溶剂)上各峰的归属;
图2为PEG化雷帕霉素的1H NMR和13C NMR谱图(CDCl3为溶剂),其中,图2(a)为1HNMR图谱的全图,图2(b)-图2(c)为1H NMR图谱的局部放大图,图2(d)为13C NMR谱图的全图,图2(e)-图2(h)为13C NMR谱图的局部放大图;
图3为本发明实施例的PEG化雷帕霉素化合物的结构式(I)。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应该理解,这些实施例仅用于说明本发明,而不用于限定本发明的保护范围。在实际应用中本领域技术人员根据本发明做出的改进和调整,仍属于本发明的保护范围。
本发明所用的原料、试剂、仪器等均可通过市售渠道购买。其中,涉及的缩写术语如下,EDC.HCl:1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐; DMAP:二甲基氨基吡啶;DMSO:二甲基亚砜;PVA:聚乙烯醇;DLS:动态激光光散色法。
一、PEG化雷帕霉素的制备与纯化
实施例1
将mPEG-COOH(简称PEG,平均分子量约为2000,0.2g,0.1mmol) 溶于CH2Cl2(8mL)中,加入RAPA(0.1g,0.1mmol),EDC.HCl(0.04g, 0.2mmol)和DMAP(0.024g,0.2mmol),振荡/搅拌使完全溶解,室温避光反应36小时,将反应液浓缩得浓缩液,浓缩液用DMSO(2mL)溶解,将所得溶液置于透析袋(截留分子量:1500Da)中,先后用DMSO、超纯水分别透析1d和2d,每4h换一次透析介质,透析液冷冻干燥得到0.074g PEG化雷帕霉素,收率23.2%。
实施例2
将mPEG-COOH(简称PEG,平均分子量约为2000,0.3007g,0.15mmol) 溶于CH2Cl2(50mL)中,加入RAPA(0.2722g,0.30mmol),EDC.HCl(0.0289 g,0.15mmol)和DMAP(0.0020g,0.15mmol),振荡/搅拌使完全溶解,室温避光搅拌反应8小时,将反应液浓缩得到含PEG化雷帕霉素浓缩液,粗产率12.1%。
实施例3
将mPEG-COOH(简称PEG,平均分子量约为2000,1.196g,0.60mmol) 溶于CH2Cl2(50mL)中,加入RAPA(0.2754g,0.30mmol),EDC.HCl(0.1157 g,0.60mmol)和DMAP(0.0070g,0.06mmol),振荡/搅拌使完全溶解,室温避光搅拌反应4小时,将反应液浓缩得到含PEG化雷帕霉素浓缩液,粗产率39.8%。
实施例4
将mPEG-COOH(简称PEG,平均分子量约为2000,1.8027g,0.90mmol) 溶于CH2Cl2(20mL)中,加入RAPA(0.2758g,0.30mmol),EDC.HCl(0.1727 g,0.90mmol)和DMAP(0.0114g,0.90mmol),振荡/搅拌使完全溶解,室温避光搅拌反应24小时,将反应液浓缩得到含PEG化雷帕霉素浓缩液,粗产率59.1%。
实施例5
将mPEG-COOH(简称PEG,平均分子量约为2000,1.8011g,0.90mmol) 溶于CH2Cl2(10mL)中,加入RAPA(0.2754g,0.30mmol),EDC.HCl(0.1720 g,0.90mmol)和DMAP(0.0105g,0.09mmol),振荡/搅拌使完全溶解,室温避光搅拌反应18小时,将反应液浓缩得到含PEG化雷帕霉素浓缩液,粗产率62.1%。使用柱层析法纯化含PEG化雷帕霉素浓缩液,见下述实施例6~8。
实施例6
在含PEG化雷帕霉素的浓缩液中,各组分比例为PEG-RAPA∶RAPA∶雷帕霉素PEG化副产物为52∶15∶9(w/w),采用硅胶柱层析,洗脱剂为二氯甲烷/ 无水甲醇(50∶1/30∶1-20∶1),洗脱时间25min/40min/120min,PEG-RAPA产率 85.3%,PEG-RAPA纯度95.9%,RAPA去除率93.2%,雷帕霉素PEG化副产物去除率90.0%。
实施例7
在含PEG化雷帕霉素的浓缩液中,各组分比例为PEG-RAPA∶RAPA∶雷帕霉素PEG化副产物为48∶13∶12(w/w),采用硅胶柱层析,洗脱剂为二氯甲烷/无水甲醇(50∶1/30∶1/10∶1),洗脱时间25min/50min/25min,PEG-RAPA产率 80.8%,PEG-RAPA纯度95.1%,RAPA去除率92.8%,雷帕霉素PEG化副产物去除率90.7%。
实施例8
在PEG化雷帕霉素的浓缩液中,各组分比例为PEG-RAPA∶RAPA∶雷帕霉素PEG化副产物为41∶11∶16(w/w),采用硅胶柱层析,洗脱剂为二氯甲烷/ 无水甲醇(50∶1/40∶1/30∶1),洗脱时间25min/70min/200min,PEG-RAPA产率 63.1%,PEG-RAPA纯度98.5%,RAPA去除率96.4%,雷帕霉素PEG化副产物去除率100.0%。
二、PEG化雷帕霉素的结构表征
实施例9
本发明采用具有如下式(II)所示结构的mPEG-COOH和雷帕霉素分子上第40位碳原子上的羟基通过酯化反应得到如下式(I)所示结构的PEG化雷帕霉素,结构表征结果如图1和图2所示。
图1中,以mPEG-COOH的1H NMR谱图中对应mPEG-COOH分子中 -CH2-COOH结构中的亚甲基上的氢原子(a)进行定标(峰面积定标为2.00), mPEG-COOH分子的重复结构单元中氢原子(b)对应的峰的面积为183.86,计算得到mPEG-COOH的聚合度为46,mPEG-COOH分子量为2114。
图2中,结合mPEG-COOH,雷帕霉素和PEG化雷帕霉素的核磁共振谱,发现雷帕霉素10-Cδ97.47,未发生较大改变;28-Cδ75.70,未发生较大改变; 40-Cδ79.31,发生较大改变,说明PEG化雷帕霉素为雷帕霉素分子中与40-C 相连的OH和mPEG-COOH发生酯化产物。
PEG化雷帕霉素的分子结构,如图3所示:
mPEG-COOH的结构简式:
二、PEG化雷帕霉素纳米粒溶液的制备
实施例10
称取20mg PEG-RAPA和2mg RAPA,加入5mLCH2Cl2使其充分溶解得有机相,取50mL含0.5%PVA的水溶液为水相,采用探头超声,在冰浴条件下,边超声边用注射器将有机相滴入水相中,超声乳化10min得白色乳剂。 40℃条件下采用旋转蒸发仪除去有机溶剂,4000r/min离心5min以去除未包封的药物和粒径较大的粒子,取上清液,即得PEG化雷帕霉素纳米粒溶液。
采用DLS法测定PEG化雷帕霉素纳米粒溶液的粒径和多分散指数(PDI,polydispersity index)。
取100μL PEG化雷帕霉素纳米粒溶液,加入乙腈至1mL,超声20min 破坏纳米粒结构,使雷帕霉素游离释放到溶液中,12000r/min离心10min,取上清液,0.22μm微孔滤膜过滤后,采用HPLC分析测定RAPA浓度,测定 PEG化雷帕霉素纳米粒的包封率和载药量。
检测结果如表1所示。
表1 PEG化雷帕霉素纳米粒的检测结果
实施例11
称取20mg PEG-RAPA和4mg RAPA,加入20mLCH2Cl2使其充分溶解得有机相,取40mL含1%PVA的水溶液为水相,采用探头超声,在冰浴条件下,边超声边用注射器将有机相滴入水相中,超声乳化20min得白色乳剂。 40℃条件下采用旋转蒸发仪除去有机溶剂,4000r/min离心5min以去除未包封的药物和粒径较大的粒子,取上清液,即得PEG化雷帕霉素纳米粒溶液。
采用DLS法测定PEG化雷帕霉素纳米粒溶液的粒径和PDI。
取100μL PEG化雷帕霉素纳米粒溶液,加入乙腈至1mL,超声20min 破坏纳米粒结构,使雷帕霉素游离释放到溶液中,12000r/min离心10min,取上清液,0.22μm微孔滤膜过滤后,采用HPLC分析测定RAPA浓度,测定 PEG化雷帕霉素纳米粒的包封率和载药量。
检测结果如表2所示。
表2 PEG化雷帕霉素纳米粒的检测结果
实施例12
称取20mg PEG-RAPA和8mg RAPA,加入40mLCH2Cl2使其充分溶解得有机相,取120mL含2%PVA的水溶液为水相,采用探头超声,在冰浴条件下,边超声边用注射器将有机相滴入水相中,超声乳化30min得白色乳剂。 40℃条件下采用旋转蒸发仪除去有机溶剂,4000r/min离心5min以去除未包封的药物和粒径较大的粒子,取上清液,即得PEG化雷帕霉素纳米粒溶液。
采用DLS法测定PEG化雷帕霉素纳米粒溶液的粒径和PDI。
取100μL PEG化雷帕霉素纳米粒溶液,加入乙腈至1mL,超声20min 破坏纳米粒结构,使雷帕霉素游离释放到溶液中,12000r/min离心10min,取上清液,0.22μm微孔滤膜过滤后,采用HPLC分析测定RAPA浓度,测定 PEG化雷帕霉素纳米粒的包封率和载药量。
检测结果如表3所示。
表3 PEG化雷帕霉素纳米粒的检测结果
三、PEG化雷帕霉素纳米粒冻干粉针剂的制备
实施例13
将按照上述实施例10-12方法制备的PEG化雷帕霉素纳米粒溶液12000 r/min离心45min,弃上清,洗去PVA,沉淀用超纯水重悬后,得浓缩纳米粒水溶液。分别取2mL纳米粒水溶液于10mL西林瓶中,加入冻干保护剂(质量分数5%),进行冻干。
(1)采用不同冻干保护剂制备PEG化雷帕霉素纳米粒冻干粉针剂
冻干保护剂质量分数为5%。取冻干保护剂0.1g置于10mL西林瓶中,分别用2mLPEG化雷帕霉素纳米粒水溶液溶解后,进行冻干。观察所制备纳米粒冻干粉针剂的外观、复溶速度、澄明度,测定复溶后纳米粒粒径和PDI。
采用不同冻干保护剂制备PEG化雷帕霉素纳米粒冻干粉针剂质量评价如表4所示。
表4采用不同冻干保护剂制备PEG化雷帕霉素纳米粒冻干粉针剂
注:1.外观+萎缩、塌陷严重,不能完全脱落;++部分萎缩、塌陷,稍有黏壁;+++没有萎缩、塌陷,可整块脱落。2.复溶速度+需要超声1min完全复溶,++需要超声30s完全复溶,+++立即复溶。3.澄明度+乳光性较差,浊度明显;++有一定乳光,但稍有浊度感;+++乳光明显,无浑浊现象
(2)采用不同预冻温度制备PEG化雷帕霉素纳米粒冻干粉针剂
分别在预冻温度为-35℃和-45℃时制备PEG化雷帕霉素纳米粒冻干粉针剂。观察所制备纳米粒冻干粉针剂的外观、复溶速度、澄明度,测定复溶后纳米粒粒径和PDI等。
采用不同预冻温度制备PEG化雷帕霉素纳米粒冻干粉针剂质量评价如表 5所示。
表5不同预冻温度制备PEG化雷帕霉素纳米粒冻干粉针剂
注:1.外观+萎缩、塌陷严重,不能完全脱落;++部分萎缩、塌陷,稍有黏壁;+++没有萎缩、塌陷,可整块脱落。2.复溶速度+需要超声1min完全复溶,++需要超声30s完全复溶,+++立即复溶。3.澄明度+乳光性较差,浊度明显;++有一定乳光,但稍有浊度感;+++乳光明显,无浑浊现象
(3)采用不同预冻方式制备PEG化雷帕霉素纳米粒冻干粉针剂
分别采用快冻法和慢冻法制备PEG化雷帕霉素纳米粒冻干粉针剂。观察所制备纳米粒冻干粉针剂的外观、复溶速度、澄明度,测定复溶后纳米粒粒径和PDI等。
采用不同预冻方式制备PEG化雷帕霉素纳米粒冻干粉针剂质量评价如表 6所示。
表6不同预冻方式制备PEG化雷帕霉素纳米粒冻干粉针剂
注:1.外观+萎缩、塌陷严重,不能完全脱落;++部分萎缩、塌陷,稍有黏壁;+++没有萎缩、塌陷,可整块脱落。2.复溶速度+需要超声1min完全复溶,++需要超声30s完全复溶,+++立即复溶。3.澄明度+乳光性较差,浊度明显;++有一定乳光,但稍有浊度感;+++乳光明显,无浑浊现象
四、两种雷帕霉素纳米粒与尿酸氧化酶联合给药对降低小鼠体内抗尿酸氧化酶抗体效果的试验
实施例14
本发明制备的PEG化雷帕霉素纳米粒(纳米粒粒径160.4nm,雷帕霉素含量:663.8μg/瓶);雷帕霉素PLGA纳米粒(纳米粒粒径170.5nm,雷帕霉素含量:294.8μg/瓶);重组假丝酵母尿酸氧化酶(含量:0.72mg/mL*7mL/ 瓶),沈阳三生制药有限责任公司沈阳研发中心。
将45只小鼠,按体重随机分为3组,每组15只。分组及给药剂量见表7。
表7药效试验剂量表
组1、组2、组3为每周给药2次,连续给药4周(根据抗尿酸氧化酶抗体检测结果,可能延长给药周期),各组均为小鼠静脉注射给药。组2和组3 给药前将尿酸氧化酶与纳米粒混合后给药。
最后一次给药之后第5天左右取小鼠全血0.5mL于非抗凝管内,分离血清后冻存检测抗尿酸氧化酶抗体。
抗尿酸氧化酶抗体检测结果如表8、表9所示:
表8给药4周抗尿酸氧化酶抗体滴度
各组小鼠尾静脉注射给药(灰色背景为尾静脉无法给药时改为腹腔注射给药,每只1~2次)4周(8次),组2(PEG化雷帕霉素聚合物纳米粒+尿酸氧化酶)抗尿酸氧化酶抗体滴度最小,组3(PLGA载雷帕霉素纳米粒+尿酸氧化酶)未见明显优于对照组1(尿酸氧化酶对照组)。
表9给药6周抗尿酸氧化酶抗体滴度
各组小鼠尾静脉注射给药(灰色背景为尾静脉无法给药时改为腹腔注射给药,每只不超过5次)6周(12次),结果基本同给药4周,且组3有3只小鼠抗体滴度增加。
尿酸氧化酶蛋白与PEG化雷帕霉素纳米粒联合用药能有效阻止小鼠体内抗尿酸氧化酶抗体的产生,且效果明显优于尿酸氧化酶蛋白与雷帕霉素PLGA 纳米粒联合用药。
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (16)
2.一种如权利要求1所述的PEG化雷帕霉素化合物的制备方法,其特征在于,将mPEG-COOH溶于有机溶剂中,加入催化剂EDC·HCl和DMAP,以及RAPA,在10~40℃避光下搅拌反应。
3.根据权利要求2所述的PEG化雷帕霉素化合物的制备方法,其特征在于,所述的有机溶剂为二氯甲烷或氯仿中的一种或两种。
4.根据权利要求2所述的PEG化雷帕霉素化合物的制备方法,其特征在于,所述的mPEG-COOH与RAPA的摩尔比为5∶1~1∶5。
5.根据权利要求2所述的PEG化雷帕霉素化合物的制备方法,其特征在于,还包括反应后的分离纯化步骤,所述的分离纯化步骤为透析纯化法或硅胶柱层析法。
6.一种纳米药物,其包括如权利要求1所述的PEG化雷帕霉素化合物。
7.根据权利要求6所述的纳米药物,其特征在于,所述的PEG化雷帕霉素化合物的有效载药量为15%-100%。
8.根据权利要求6所述的纳米药物,其特征在于,还包括雷帕霉素。
9.一种如权利要求6~8任一项所述的纳米药物的制备方法,其特征在于,将PEG化雷帕霉素化合物,或PEG化雷帕霉素化合物和雷帕霉素溶解在有机溶剂中形成有机相,然后加入到含有聚乙烯醇的水相中,通过高速搅拌、超声、漩涡振荡和/或用高压匀质机制成水包油乳状液,最后经蒸发、挥干有机溶剂得到PEG化雷帕霉素纳米粒溶液。
10.根据权利要求9所述的纳米药物的制备方法,其特征在于,所述的PEG化雷帕霉素在所述的有机相中的浓度为0.1-10mg/mL;所述的聚乙烯醇在所述的水相中的浓度为0-5%(w/v),所述的有机相/所述的水相的比例为1/1-1/100(v/v)。
11.一种冻干制剂,其特征在于,其由如权利要求9所述的PEG化雷帕霉素纳米粒的水溶液和冻干保护剂冻干制得。
12.根据权利要求11所述的冻干制剂,其特征在于,所述的冻干保护剂为蔗糖、乳糖、甘露醇、葡萄糖、海藻糖、麦芽糖中的一种或多种。
13.一种药物组合物,其包括治疗有效剂量的如权利要求1所述的PEG化雷帕霉素化合物及可药用的载体。
14.根据权利要求13所述的药物组合物,其特征在于,还包括生物药物。
15.根据权利要求14所述的药物组合物,其特征在于,所述的生物药物为尿酸氧化酶、酶和辅酶类药物、核酸及其降解物和衍生物类药物、细胞生长因子或细胞因子中的一种或多种。
16.权利要求1所述的PEG化雷帕霉素化合物,权利要求6~8任一项所述的纳米药物,权利要求11所述的冻干制剂或权利要求13~15任一项所述的药物组合物在制备用于减少免疫应答的药物中的用途。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110365285.9A CN115160559B (zh) | 2021-04-02 | 2021-04-02 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
PCT/CN2022/083907 WO2022206796A1 (zh) | 2021-04-02 | 2022-03-30 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
US18/252,309 US20240009228A1 (en) | 2021-04-02 | 2022-03-30 | Pegylated rapamycin compound and preparation method therefor and application thereof |
JP2023523642A JP2023545563A (ja) | 2021-04-02 | 2022-03-30 | Peg化ラパマイシン化合物、その調製方法及び使用 |
EP22778978.1A EP4316523A1 (en) | 2021-04-02 | 2022-03-30 | Pegylated rapamycin compound, and preparation method therefor and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110365285.9A CN115160559B (zh) | 2021-04-02 | 2021-04-02 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115160559A true CN115160559A (zh) | 2022-10-11 |
CN115160559B CN115160559B (zh) | 2024-02-02 |
Family
ID=83457964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110365285.9A Active CN115160559B (zh) | 2021-04-02 | 2021-04-02 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240009228A1 (zh) |
EP (1) | EP4316523A1 (zh) |
JP (1) | JP2023545563A (zh) |
CN (1) | CN115160559B (zh) |
WO (1) | WO2022206796A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104448295A (zh) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 |
CN104689330A (zh) * | 2013-12-06 | 2015-06-10 | 上海交通大学 | 抗肿瘤药物peg化及其在逆转肿瘤多药耐药上的应用 |
WO2018053434A1 (en) * | 2016-09-16 | 2018-03-22 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
-
2021
- 2021-04-02 CN CN202110365285.9A patent/CN115160559B/zh active Active
-
2022
- 2022-03-30 EP EP22778978.1A patent/EP4316523A1/en active Pending
- 2022-03-30 JP JP2023523642A patent/JP2023545563A/ja active Pending
- 2022-03-30 US US18/252,309 patent/US20240009228A1/en active Pending
- 2022-03-30 WO PCT/CN2022/083907 patent/WO2022206796A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104448295A (zh) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物 |
CN104689330A (zh) * | 2013-12-06 | 2015-06-10 | 上海交通大学 | 抗肿瘤药物peg化及其在逆转肿瘤多药耐药上的应用 |
WO2018053434A1 (en) * | 2016-09-16 | 2018-03-22 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
US20190255189A1 (en) * | 2016-09-16 | 2019-08-22 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2023545563A (ja) | 2023-10-30 |
EP4316523A1 (en) | 2024-02-07 |
WO2022206796A1 (zh) | 2022-10-06 |
CN115160559B (zh) | 2024-02-02 |
US20240009228A1 (en) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2133175C (en) | Rapamycin formulations for oral administration | |
KR100421451B1 (ko) | 안정한 고분자 미셀 조성물 및 그의 제조방법 | |
JP3363907B2 (ja) | マクロライドまたはサイクロスポリンとポリエトキシル化水酸化脂肪酸を含む医薬組成物 | |
RU2375384C2 (ru) | Новый блок-сополимер, мицеллярный препарат и противораковое средство, включающее мицеллярный препарат в качестве активного ингредиента | |
AU9362398A (en) | Pharmaceutical compositions containing plasma protein | |
JP2002526383A (ja) | 薬物分子と生分解性高分子の共有結合を用いた薬物分子伝達システム | |
JP2002535242A (ja) | 新規な粒子状剤型 | |
EP1604687B1 (en) | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer | |
CN103143028A (zh) | 巯基化两亲性壳聚糖聚合物载体及其药学组合物的制备及应用 | |
CN109646403B (zh) | 一种无载体大环内酯类免疫抑制药物纳米粒的制备方法 | |
CN103006539A (zh) | 一种聚合物胶束药物组合物及其制备方法 | |
Press et al. | Natural product drug delivery: a special challenge? | |
AU2022366465A1 (en) | AUTOIMMUNE DISEASE THERAPEUTIC AGENT INCLUDING OLIGONUCLEOTIDE THAT SELECTIVELY BINDS TO IFN-γ, AND SAID OLIGONUCLEOTIDE | |
EP0650730A1 (en) | Rapamycin formulations for oral administration | |
JP2004018494A (ja) | ブロック共重合体−薬剤複合体の製造法 | |
CN113651959B (zh) | 一种基于氨基酸-羟基酸共聚物的纳米载药体系及其制备方法和应用 | |
CN115160559B (zh) | 一种peg化雷帕霉素化合物及其制备方法与应用 | |
WO2021113643A2 (en) | Methods and compositions for synthesis of therapeutic nanoparticles | |
CN109475498A (zh) | 包含水难溶性药物的聚合物胶束制剂的体外释放试验及评价方法 | |
CN110812335B (zh) | 装载疏水药物的丝素蛋白微纳米颗粒缓释制剂及制备方法 | |
CN104523608A (zh) | 一种适用于疏水药物的亲水性酰胺类聚合物自组装微粒释药系统及其制备方法 | |
CN110123748A (zh) | 一种叶酸介导的靶向双载药聚合物胶束及其制备方法和应用 | |
CN110339163B (zh) | 一种顺铂-聚谷氨酸络合胶束及其制备方法 | |
CN106957418B (zh) | 一种被修饰的嵌段共聚物及其制备方法和用途 | |
CN115109258A (zh) | 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |